NOTICE TO STAKEHOLDERS

WITHDRAWAL OF THE UNITED KINGDOM AND EU RULES IN THE FIELD OF SUBSTANCES OF HUMAN ORIGIN (BLOOD, TISSUES AND CELLS, AND ORGANS)

The United Kingdom submitted on 29 March 2017 the notification of its intention to withdraw from the Union pursuant to Article 50 of the Treaty on European Union. This means that, unless a ratified withdrawal agreement establishes another date, all Union primary and secondary law will cease to apply to the United Kingdom from 30 March 2019, 00:00h (CET) (‘the withdrawal date’). The United Kingdom will then become a 'third country'.

Preparing for the withdrawal is not just a matter for EU and national authorities but also for private parties.

In view of the considerable uncertainties, in particular concerning the content of a possible withdrawal agreement, health establishments, stakeholders and organisations subject to the Union legislation on substances of human origin (blood, tissues and cells, and organs) are reminded of legal repercussions, which need to be considered when the United Kingdom becomes a third country.

Subject to any transitional arrangement that may be contained in a possible withdrawal agreement, as of the withdrawal date, the EU rules in the field of substances of human origin (blood, tissues and cells, and organs) no longer apply to the United Kingdom. This has, in particular, the following consequences in the different areas:

- **Blood and blood components:** According to Article 21 (second subparagraph) of Directive 2002/98/EC, imports of blood and blood components from the United Kingdom will need to be tested in conformity with the Union testing requirements

---

1 Negotiations are ongoing with the United Kingdom with a view to reaching a withdrawal agreement.

2 Furthermore, in accordance with Article 50(3) of the Treaty on European Union, the European Council, in agreement with the United Kingdom, may unanimously decide that the Treaties cease to apply at a later date.

3 A third country is a country not member of the EU.

(Annex IV to that Directive). They will also need to meet equivalent standards of quality and safety (Annex V to Directive 2004/33/EC\(^5\)).

- **Tissues and cells:** Imports of tissues and cells from the United Kingdom will have to be undertaken by authorised importing tissue establishments located in the EU-27 (Article 9(1) of Directive 2004/23/EC\(^6\)) and meet standards of quality and safety equivalent to those laid down in the Union legislation (Article 9(1) of Directive 2004/23/EC and Directive (EU) 2015/566\(^7\)). Directive 2004/23/EC also establishes, in Article 9(2), rules for export of tissues or cells to third countries. In particular, those Member States that export tissues or cells to third countries must ensure that the exports comply with the requirements of this Directive. Moreover, according to Article 9(3) of Directive 2004/23/EC, in some cases (where certain specific tissues and cells are distributed directly for immediate transplantation to the recipient or in case of emergency) the import or export of tissues and cells may be authorised directly by the competent authority, as long as such imports and exports meet quality and safety standards equivalent to those laid down in Directive 2004/23/EC and implementing legislation.

- **Organs:** According to Article 20 of Directive 2010/53/EU\(^8\), exchange of organs with the United Kingdom will need to be supervised by an EU-27 competent authority or European organ exchange organisations (where the Member State delegates the supervision to them) and meet quality and safety requirements equivalent to those laid down in the Union legislation.

In accordance with the aforementioned legislation, in all cases, blood, tissues and cells, and organs will need to be **traceable from donor to recipient and vice versa**.

The website of the Commission on blood, tissues and organs (https://ec.europa.eu/health/blood_tissues_organs/policy_en) provide for general information. These pages will be updated with further information, where necessary.

---


